What question did this study set out to answer?

To evaluate the complete response rate, progression-free survival, and feasibility of dose-intensive chemoimmunotherapy consolidation without whole-brain radiotherapy in newly diagnosed primary CNS lymphoma.

April 8, 2013Journal of Clinical OncologyOpen Access

Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

View Full Paper

Ask AI

Bookmark

Authors

JRJames L. Rubenstein EHEric D. Hsi JJJeffrey L. Johnson

Discussion

Member takes

Overview

Multicenter trial demonstrates high progression-free survival without whole-brain radiotherapy in primary CNS lymphoma, indicating radiation-free intensive consolidation is feasible.

Key Points

To evaluate the complete response rate, progression-free survival, and feasibility of dose-intensive chemoimmunotherapy consolidation without whole-brain radiotherapy in newly diagnosed primary CNS lymphoma.
Multicenter prospective study evaluating 44 patients with newly diagnosed primary CNS lymphoma.
Induction therapy consisted of methotrexate, temozolomide, and rituximab (MT-R), followed by high-dose consolidation with etoposide plus cytarabine (EA) for patients achieving complete response.
Assessed clinical prognostic factors and prospectively evaluated molecular biomarkers, including BCL6 expression, across a median follow-up of 4.9 years.
The complete response rate following MT-R induction therapy was 66%.
Overall 2-year progression-free survival was 0.57, with a 2-year time to progression of 0.59 overall and 0.77 for patients completing EA consolidation.
Patients older than 60 years achieved outcomes comparable to younger cohorts, treatment delay was the most significant clinical risk factor, and high BCL6 expression correlated with shorter survival.

Cite This Study

Rubenstein et al. (2013) studied this question.

synapsesocial.com/papers/69f20c8fba0eb63c1ddd338d https://doi.org/10.1200/jco.2012.46.9957

View Full Paper

Ask AI

Bookmark

April 8, 2013Journal of Clinical OncologyOpen Access

Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

View Full Paper

Ask AI

Bookmark

Authors

JRJames L. Rubenstein EHEric D. Hsi JJJeffrey L. Johnson

Discussion

Member takes

Overview

Multicenter trial demonstrates high progression-free survival without whole-brain radiotherapy in primary CNS lymphoma, indicating radiation-free intensive consolidation is feasible.

Key Points

To evaluate the complete response rate, progression-free survival, and feasibility of dose-intensive chemoimmunotherapy consolidation without whole-brain radiotherapy in newly diagnosed primary CNS lymphoma.
Multicenter prospective study evaluating 44 patients with newly diagnosed primary CNS lymphoma.
Induction therapy consisted of methotrexate, temozolomide, and rituximab (MT-R), followed by high-dose consolidation with etoposide plus cytarabine (EA) for patients achieving complete response.
Assessed clinical prognostic factors and prospectively evaluated molecular biomarkers, including BCL6 expression, across a median follow-up of 4.9 years.
The complete response rate following MT-R induction therapy was 66%.
Overall 2-year progression-free survival was 0.57, with a 2-year time to progression of 0.59 overall and 0.77 for patients completing EA consolidation.
Patients older than 60 years achieved outcomes comparable to younger cohorts, treatment delay was the most significant clinical risk factor, and high BCL6 expression correlated with shorter survival.

Cite This Study

Rubenstein et al. (2013) studied this question.

synapsesocial.com/papers/69f20c8fba0eb63c1ddd338d https://doi.org/10.1200/jco.2012.46.9957

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark